Investor Fairmount Funds Management LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Fairmount Funds Management LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-09-19 13D/A ORKA / Oruka Therapeutics, Inc. 8,511,824 11,162,741
2025-09-15 13D/A DNTH / Dianthus Therapeutics, Inc. 2,957,385 4,052,052
2025-08-14 13G/A ELVN / Enliven Therapeutics, Inc. 3,202,798 3,711,444
2025-07-14 13D/A COGT / Cogent Biosciences, Inc. 11,330,141 14,324,918
2025-06-23 13D CBIO / Crescent Biopharma, Inc. 3,124,220
2025-05-01 13D JBIO / Jade Biosciences, Inc. 7,249,356
2025-03-10 13D/A ORKA / Oruka Therapeutics, Inc. 7,941,690 8,511,824
2025-02-14 13G/A ELVN / Enliven Therapeutics, Inc. 3,202,798 3,202,798
2025-02-14 13G/A IKT / Inhibikase Therapeutics, Inc. 6,620,311 7,018,575
2025-02-14 13G/A KNSA / Kiniksa Pharmaceuticals, Ltd. 3,204,841 0
2025-02-14 13G/A ANAB / AnaptysBio, Inc. 0
2025-02-14 13G/A ATXS / Astria Therapeutics, Inc. 5,868,045 5,869,037
2024-12-18 13G ANAB / AnaptysBio, Inc. 1,671,484
2024-11-21 13D/A ORKA / Oruka Therapeutics, Inc. 7,941,673 7,941,690
2024-11-14 13G/A KNSA / Kiniksa Pharmaceuticals, Ltd. 2,883,221 3,204,841
2024-11-14 13G/A TERN / Terns Pharmaceuticals, Inc. 6,632,015 0
2024-11-14 13G/A ATXS / Astria Therapeutics, Inc. 3,633,965 5,868,045
2024-11-14 13G/A ELVN / Enliven Therapeutics, Inc. 2,131,369 3,202,798
2024-10-17 13G IKT / Inhibikase Therapeutics, Inc. 6,620,311
2024-09-17 13D/A VRDN / Viridian Therapeutics, Inc. 13,956,685 15,556,685
2024-09-13 13D/A ORKA / Oruka Therapeutics, Inc. 6,611,255 7,941,673
2024-09-06 13D ORKA / Oruka Therapeutics, Inc. 6,611,255
2024-06-13 13D/A COGT / Cogent Biosciences, Inc. 9,986,556 11,330,141
2024-04-25 13D/A SYRE / Spyre Therapeutics, Inc. 836,459 4,508,579
2024-04-01 13D/A VRDN / Viridian Therapeutics, Inc. 13,956,685 13,956,685
2024-04-01 13D/A DNTH / Dianthus Therapeutics, Inc. 2,960,747 2,957,385
2024-04-01 13D/A COGT / Cogent Biosciences, Inc. 10,018,075 9,986,556
2024-04-01 13D/A APGE / Apogee Therapeutics, Inc. 5,403,053 4,762,558
2024-03-27 13D/A COGT / Cogent Biosciences, Inc. 23,079,141 10,018,075
2024-02-16 13D/A COGT / Cogent Biosciences, Inc. 19,962,564 23,079,141
2024-02-14 13G/A NUVL / Nuvalent, Inc. 2,788,981 1,924,626
2024-02-14 13G/A TERN / Terns Pharmaceuticals, Inc. 5,269,287 6,632,015
2024-02-14 13G/A ATXS / Astria Therapeutics, Inc. 1,901,397 3,633,965
2024-02-14 13G/A TRVI / Trevi Therapeutics, Inc. 6,018,465 0
2024-02-14 13G/A KNSA / Kiniksa Pharmaceuticals, Ltd. 2,143,052 2,883,221
2024-02-14 13G/A AXSM / Axsome Therapeutics, Inc. 2,344,980 2,360,077
2024-02-14 13G/A ANNX / Annexon, Inc. 3,681,456 322,893
2024-02-14 13G/A ELVN / Enliven Therapeutics, Inc. 2,124,625 2,131,369
2024-01-31 13D/A APGE / Apogee Therapeutics, Inc. 3,906,202 5,403,053
2024-01-24 13D/A DNTH / Dianthus Therapeutics, Inc. 1,873,833 2,960,747
2024-01-24 13D/A VRDN / Viridian Therapeutics, Inc. 12,764,393 13,956,685
2023-12-29 13D/A SYRE / Spyre Therapeutics, Inc. 3,813,901 836,459
2023-12-11 13D/A SYRE / Spyre Therapeutics, Inc. 3,813,901 3,813,901
2023-11-29 13D/A SYRE / Spyre Therapeutics, Inc. 3,813,901
2023-11-03 13D/A VRDN / Viridian Therapeutics, Inc. 9,192,814 12,764,393
2023-10-10 13G SLNO / Soleno Therapeutics, Inc. 950,000
2023-09-21 13D DNTH / Dianthus Therapeutics, Inc. 1,873,833
2023-08-10 13G KNSA / Kiniksa Pharmaceuticals, Ltd. 2,143,052
2023-07-21 13D APGE / Apogee Therapeutics, Inc. 3,906,202
2023-07-07 13G AXSM / Axsome Therapeutics, Inc. 2,011,647 2,344,980
2023-06-30 13D AGLE / Aeglea BioTherapeutics Inc 19,590,000
2023-06-13 13D/A COGT / Cogent Biosciences, Inc. 15,230,473 19,962,564
2023-04-27 13G ELVN / Enliven Therapeutics, Inc. 2,124,625
2023-02-14 13G/A ATXS / Astria Therapeutics, Inc. 911,736 1,901,397
2023-02-14 13G/A AXSM / Axsome Therapeutics, Inc. 2,166,647 2,011,647
2023-02-14 13G/A TERN / Terns Pharmaceuticals, Inc. 2,050,000 5,269,287
2023-02-14 13G/A ANNX / Annexon, Inc. 2,569,400 3,681,456
2023-02-14 13G/A OLMA / Olema Pharmaceuticals, Inc. 2,107,873 0
2023-02-14 13G/A TRVI / Trevi Therapeutics, Inc. 3,759,510 6,018,465
2023-02-14 13G/A NUVL / Nuvalent, Inc. 2,605,124 2,788,981
2022-11-09 13G NUVL / Nuvalent, Inc. 2,605,124
2022-10-26 13G AXSM / Axsome Therapeutics, Inc. 2,166,647
2022-08-25 13G TERN / Terns Pharmaceuticals, Inc. 2,050,000
2022-08-19 13D/A VRDN / Viridian Therapeutics, Inc. 3,460,351 9,192,814
2022-06-21 13D/A COGT / Cogent Biosciences, Inc. 7,482,460 15,230,473
2022-04-21 13G ANNX / Annexon, Inc. 2,569,400
2022-04-21 13G TRVI / Trevi Therapeutics, Inc. 3,759,510
2022-02-11 13G OLMA / Olema Pharmaceuticals, Inc. 2,107,873
2022-02-08 13G/A ATXS / Astria Therapeutics, Inc. 974,605 911,736
2021-09-23 13D/A VRDN / Viridian Therapeutics, Inc. 967,671 3,460,351
2021-09-22 13G/A ATXS / Astria Therapeutics, Inc. 4,092,166 974,605
2021-06-17 13G ATXS / Astria Therapeutics, Inc. 4,092,166
2021-01-05 13D VRDN / Viridian Therapeutics, Inc. 967,671
2021-01-05 13D VRDN / Viridian Therapeutics, Inc. 967,671
2020-07-10 13D COGT / Cogent Biosciences, Inc. 7,482,460 7,482,460
2020-07-09 13D COGT / Cogent Biosciences, Inc. 7,482,460